US President Donald Trump has announced deals that aim to lower the cost of popular weight loss drugs, as phramaceutical prices take centre stage in his administration's messaging around affordability ...
On May 12, 2025, President Trump signed an Executive Order titled: “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients” directing the Administration to take numerous actions ...
President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices ...
Despite quarterly revenue totals that were nearly cut in half compared to the same period last year, Moderna still expects to ...
India's pharmaceutical market thrives as a global generic medicine leader, expanding in vaccines and APIs. With strong R&D, policy support, and global healthcare spikes, it's set for growth.
The “most favored nation” (MFN) drug pricing deal AstraZeneca recently signed with the Trump administration won’t affect the ...
Lupin's consolidated profit rose 73% YoY to Rs 1,478 crore in Q2 FY26, led by robust sales in India and the US and higher margins from an improved product mix ...
Understand the challenges and solutions around pharmacy benefits as costs rise and new drugs enter the market.
Five top-selling drugs, in some cases, are costing Americans thousands in out of pocket expenses weekly and monthly. Here's ...
UnitedHealth Group remains a top pick with strong EPS growth, AI-driven savings, and steady revenues. Click here to read an ...
Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback